RDY
Dr. Reddy’s Laboratories Ltd ADR
NYSE: RDY · HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC
$13.73
-2.14% today
Updated 2026-04-29
Market cap
$11.46B
P/E ratio
19.07
P/S ratio
0.03x
EPS (TTM)
$0.72
Dividend yield
0.67%
52W range
$13 – $16
Volume
2.4M
WallStSmart proprietary scores
53
out of 100
Grade: C
Hold
Investment rating
4.7
Growth
C7.5
Quality
B+7.5
Profitability
B+4.3
Valuation
C2/9
Piotroski F-Score
Weak
3.7
Altman Z-Score
Safe zone
—
Industry rank
—
View all highly rated stocks (75+) →204 stocks currently score above 75
Price targets
Analyst target
$14.10
+2.69%
12-Month target
$13.43
-2.18%
Intrinsic (DCF)
—
Margin of safety
—
0 Strong Buy2 Buy2 Hold1 Sell0 Strong Sell
Price chart
X-Ray snapshot
Strengths
+ Altman Z 3.68 — safe zone
+ Free cash flow $3.59B — positive
+ Debt/equity 0.18x — low leverage
Risks
- Piotroski 2/9 — weak financial health
Key financials
Revenue Net Income Free Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Revenue | $214.39B | $245.88B | $279.16B | $325.54B | $345.83B |
| Net income | $23.57B | $45.07B | $55.68B | $56.54B | $12.10B |
| EPS | — | — | — | — | $0.72 |
| Free cash flow | $9.06B | $40.01B | $18.00B | $12.03B | $3.59B |
| Profit margin | 10.99% | 18.33% | 19.95% | 17.37% | 16.40% |
Peer comparison
Smart narrative
Dr. Reddy’s Laboratories Ltd ADR trades at $13.73. representing a P/E of 19.07x trailing earnings. Our Smart Value Score of 53/100 indicates the stock is fair. The company scores 2/9 on the Piotroski F-Score. With an Altman Z-Score of 3.68, it sits in the safe zone. TTM revenue stands at $345.83B. with profit margins at 16.40%.
Frequently asked questions
What is Dr. Reddy’s Laboratories Ltd ADR's stock price?
Dr. Reddy’s Laboratories Ltd ADR (RDY) trades at $13.73.
Is Dr. Reddy’s Laboratories Ltd ADR overvalued?
Smart Value Score 53/100 (Grade C, Hold).
What is the price target of Dr. Reddy’s Laboratories Ltd ADR (RDY)?
The analyst target price is $14.10, representing +2.7% upside from the current price of $13.73.
What is the future stock price of RDY by 2030?
Our revenue-driven model estimates Dr. Reddy’s Laboratories Ltd ADR could reach $20.95 by 2030, based on historical CAGR, margin trends, and capped P/E multiples.
What is Dr. Reddy’s Laboratories Ltd ADR's revenue?
TTM revenue is $345.83B.
Piotroski F-Score?
2/9 — weak financial health.
Altman Z-Score?
3.68 — safe zone.
Company info
SectorHEALTHCARE
IndustryDRUG MANUFACTURERS - SPECIALTY & GENERIC
CountryUSA
ExchangeNYSE
CurrencyUSD
Quick metrics
P/S ratio0.03x
ROE16.10%
Beta0.30
50D MA$13.83
200D MA$14.00
Shares out0.83B
Float0.60B
Short ratio—
Avg volume2.4M
Performance
1 week+1.10%
1 month-0.87%
3 months+3.47%
YTD-2.21%
1 year—
3 years—
5 years—